Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Eloxx reports $56.3m cash as exaluren advances in two rare kidney diseases

The company says its balance sheet should last into 2028, covering a mid-2027 Alport readout and a planned Q3 2027 start in polycystic kidney disease.

16 Nov 2026 · Eloxx Pharmaceuticals, Inc. ELOX · Company news

Eloxx Pharmaceuticals ended the third quarter of 2026 with $56.3 million in cash, which it expects to fund operations into 2028. The figure came with the company's results on 16 November, and it matters because exaluren, its lead asset, is now moving in two separate kidney indications.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Eloxx Pharmaceuticals, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →